HBM Partners's book
21 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | — | |
| Parabilis Medicines | Drug Discovery | $920.0M | — | — | |
| Odyssey Therapeutics | Biotechnology | $638.2M | — | — | |
| Nuance Pharma | — | $623.1M | — | — | |
| Egenesis | — | $330.0M | — | — | |
| Neuron23 | — | $271.5M | — | — | |
| connectRN | — | $256.0M | — | — | |
| Fore Biotherapeutics | — | $198.2M | — | — | |
| Karius | — | $185.0M | — | — | |
| Adrenomed | — | $133.9M | — | — | |
| + 11 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 21 recorded positions
- ·Watchlist + alerts for HBM Partners's activity
Create free account
No card required